Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TN6K
|
|||
| Drug Name |
LSZ102
|
|||
| Synonyms |
SJXNPGGVGZXKKI-NYYWCZLTSA-N; LSZ-102; 2135600-76-7; (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid; SCHEMBL17334098; BDBM269484; EX-A1874; BCP29222; HY-111486; CS-0042193; US10058534, 139; (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo [b]thiophen-3-yl)oxy)phenyl)acrylic acid; C6V; (2E)-3-[4-({2-[2-(1,1-difluoroethyl)-4-fluorophenyl]-6-hydroxy-1-benzothiophen-3-yl}oxy)phenyl]prop-2-enoic acid
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | |
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H17F3O4S
|
|||
| Canonical SMILES |
CC(C1=C(C=CC(=C1)F)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)C=CC(=O)O)(F)F
|
|||
| InChI |
1S/C25H17F3O4S/c1-25(27,28)20-12-15(26)5-9-18(20)24-23(19-10-6-16(29)13-21(19)33-24)32-17-7-2-14(3-8-17)4-11-22(30)31/h2-13,29H,1H3,(H,30,31)/b11-4+
|
|||
| InChIKey |
SJXNPGGVGZXKKI-NYYWCZLTSA-N
|
|||
| CAS Number |
CAS 2135600-76-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.